MYCN and neoplasm: This data supports previously reported tumor-associated immune subsets in the Th-MYCN model and clinical neuroblastoma samples as reviewed by Wienke and colleagues28; however, proportions may vary owing to different analytical techniques and tumor stage29,30 (Fig. 4f; Supp.